|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
41,310,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Talaris Therapeutics is a late-clinical stage, cell therapy company developing a method of allogeneic hematopoietic stem cell transplantation, called Facilitated Allo-HSCT Therapy, that has the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases and certain severe blood, immune and metabolic disorders. Co.'s lead product candidate, FCR001, which is central to its Facilitated Allo-HSCT Therapy, is an allogeneic cell therapy comprised of stem and immune cells that are procured from a healthy donor, who is also the organ donor in the case of organ transplantation.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
107,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$3,348,416 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2025-09-14 |
2025-06-13 |
2024-12-13 |
2023-12-14 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Novartis Ag |
10% Owner |
– – • |
2025-10-28 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
24,030,382 |
|
- |
|
| Kulkarni Sandeep Chidambar |
CEO |
• • – |
2025-10-28 |
4 |
D |
$0.00 |
$0 |
I/I |
(7,000) |
0 |
|
- |
|
| Kulkarni Sandeep Chidambar |
CEO |
• • – |
2025-10-28 |
4 |
D |
$0.00 |
$0 |
D/D |
(30,387) |
0 |
|
- |
|
| Kulkarni Sandeep Chidambar |
CEO |
• • – |
2025-10-28 |
4 |
D |
$0.00 |
$0 |
D/D |
(724,664) |
30,387 |
|
- |
|
| Castelein Caley |
|
– • – |
2025-10-28 |
4 |
D |
$0.00 |
$0 |
I/I |
(431,939) |
0 |
|
- |
|
| Castelein Caley |
|
– • – |
2025-10-28 |
4 |
D |
$0.00 |
$0 |
D/D |
(515,997) |
0 |
|
- |
|
| Robinson Ryan F. |
CFO |
• – – |
2025-10-28 |
4 |
D |
$0.00 |
$0 |
D/D |
(14,366) |
0 |
|
- |
|
| Kantoff Aaron |
|
– • – |
2025-10-28 |
4 |
D |
$0.00 |
$0 |
D/D |
(88,281) |
0 |
|
- |
|
| Middlekauff W Bradford |
CBO, GC and Secretary |
• – – |
2025-10-28 |
4 |
D |
$0.00 |
$0 |
D/D |
(8,213) |
0 |
|
- |
|
| Middlekauff W Bradford |
CBO, GC and Secretary |
• – – |
2025-10-28 |
4 |
D |
$0.00 |
$0 |
D/D |
(60,988) |
8,213 |
|
- |
|
| Thiara Parvinder |
|
– • – |
2025-10-28 |
4 |
D |
$0.00 |
$0 |
D/D |
(83,782) |
0 |
|
- |
|
| Mcdade Mark |
|
– • – |
2025-10-28 |
4 |
D |
$0.00 |
$0 |
I/I |
(741,691) |
0 |
|
- |
|
| Mcdade Mark |
|
– • – |
2025-10-28 |
4 |
D |
$0.00 |
$0 |
D/D |
(518) |
0 |
|
- |
|
| Srivastava Sapna |
|
– • – |
2025-10-28 |
4 |
D |
$0.00 |
$0 |
D/D |
(518) |
0 |
|
- |
|
| Jones Susan Dana |
Chief Technology Officer |
• – – |
2025-10-28 |
4 |
D |
$0.00 |
$0 |
D/D |
(3,152) |
0 |
|
- |
|
| Jones Susan Dana |
Chief Technology Officer |
• – – |
2025-10-28 |
4 |
D |
$0.00 |
$0 |
D/D |
(19,782) |
3,152 |
|
- |
|
| Johnson Kevin Bruce |
Chief Regulatory Officer |
• – – |
2025-10-28 |
4 |
D |
$0.00 |
$0 |
D/D |
(11,046) |
0 |
|
- |
|
| Johnson Kevin Bruce |
Chief Regulatory Officer |
• – – |
2025-10-28 |
4 |
D |
$0.00 |
$0 |
D/D |
(40,538) |
11,046 |
|
- |
|
| Kantoff Aaron |
|
– • – |
2025-10-24 |
4 |
GD |
$0.00 |
$0 |
D/D |
5,000 |
88,281 |
|
- |
|
| Robinson Ryan F. |
CFO |
• – – |
2025-10-22 |
4 |
OE |
$13.92 |
$199,975 |
D/D |
14,366 |
14,366 |
|
- |
|
| Kulkarni Sandeep Chidambar |
CEO |
• • – |
2025-10-22 |
4 |
OE |
$7.90 |
$199,996 |
D/D |
25,316 |
755,051 |
|
- |
|
| Castelein Caley |
|
– • – |
2025-10-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
522 |
515,997 |
|
- |
|
| Johnson Kevin Bruce |
Chief Regulatory Officer |
• – – |
2025-10-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
6,250 |
51,584 |
|
- |
|
| Kantoff Aaron |
|
– • – |
2025-09-05 |
4 |
OE |
$0.13 |
$99,526 |
D/D |
47,890 |
93,281 |
|
- |
|
| Kulkarni Sandeep Chidambar |
CEO |
• • – |
2024-08-21 |
4 |
B |
$14.85 |
$26,418 |
I/I |
1,779 |
7,000 |
2.66 |
- |
|
115 Records found
|
|
Page 1 of 5 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
